Navigation Links
Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
Date:5/14/2008

BRISBANE, Australia, May 14 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX:PGL; Nasdaq: PGLA) today announced that the Company has resumed patient enrolment in the phase 1 dose-escalation study of its recently acquired polyamine analogue, PG-11047 (formerly CGC-11047) for patients with advanced cancer.

Progen has commenced development of PG-11047 - the lead clinical compound in the Company's polyamine program - following its acquisition of Cellgate, Inc earlier this year. The first patient to be recruited into the trial re-initiation has been enrolled at the University of Chicago.

The trial is exploring the potential of PG-11047 as a single anti-cancer agent and is designed to assess the agent's maximum tolerated dose. Under CellGate, the trial had recruited 31 patients and had shown little evidence of toxicity, while using significantly higher doses than most previous studies of polyamine compounds.

Justus Homburg, Progen's CEO, said, "Since the acquisition of CellGate, we have been assessing our portfolio of clinical and pre-clinical compounds in order to determine which to drive forward. Our re-initiation of PG-11047 in phase 1 clinical development is the first step in driving potential value from our expanded portfolio of first-in-class oncology therapies."

Data from the trial will be used in parallel with a separate PG-11047 study assessing the agent in combination with other marketed anti-cancer drugs as the basis for determining potential phase 2 development. Progen expects the study to produce data within the next 12 months.

About Progen: Progen Pharmaceuticals is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has operations in Australia and the US.

About PG-11047: PG-11047 is a polyamine analogue which modifies the production of natural polyamines. Polyamines a
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
3. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
4. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
5. Progen Announces PI-88 Phase 2 Lung Cancer Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
11. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... SAN DIEGO, Oct. 7 /- Prometheus Lab..., today announced findings from its,development of...blood test,for irritable bowel syndrome (IBS). The...pression of particular biomarkers in blood samples...ion of these biomarkers,combined with a proprieta...
(Date:10/7/2008)... Results of FLEXX Trial Presented at the Osteoart... Congress, PARSIPPANY, N.J., Oct. 7 /PRNewswire/ ... results from the FLEXX Trial of Osteoarthritis of...luronate), a highly pure,non-avian high molecular ...-HA), is superior to intra-articular saline (IA-sa...
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken onc...D within one week, PHILADELPHIA, Oct. 7 /PRNewswi...Y), the global specialty biopharmaceutical company...ptember issue of the Journal of,Clinical Psychiatr...Attention Deficit Hyperactivity Disorder (ADHD) sy...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aerovan...fety data from a Phase I trial of its Aerovant,inh...with no evidence of,local irritancy following asth...This 10 mg dose will be the highest of three doses...g study, which is scheduled to begin early,next ye...
Breaking Medicine Technology:Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2EuroDYNA takes lid off the genome 3629 1EuroDYNA takes lid off the genome 3629 2EuroDYNA takes lid off the genome 3629 3EuroDYNA takes lid off the genome 3629 41 in 10 adults has a non earlobe piercing 21798 11 in 10 adults has a non earlobe piercing 21798 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 1New insight into RA patient priorities and motivators for clinical trial involvement 21796 2New insight into RA patient priorities and motivators for clinical trial involvement 21796 3New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 1New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 2New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 3New STAY ON TRACK for Better Prostate Health Program Launches Fathers Day Weekend at NASCAR Race 21794 4
...ALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd...ompany, reported,today pre-clinical data from tria...ive in preventing deterioration of the myocardium,...ng left ventricle,dilatation and eventual heart fa... Director of the Neufeld Cardiac Research,Institut...
...t-Ever Placebo-controlled Study in Inoperable Chro...y Endpoint of,Reduction in Pulmonary Vascular Resi...ificant Effect on Dyspnoea Score and,Biological Di..., 2007 -Actelion Ltd (SWX:,ATLN) announced today t...controlled, multicenter study BENEFiT (Bosentan Ef...
Other Medicine Technology:BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 2Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 3Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 4Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 5Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH 6
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...an to reduce illegal trading and as a clean up dri...couver. Vancouver’s mayor is considering providing...town Eastside before the 2010 Winter Olympics. Ac...an anonymous donor of $500,000 to fund an innovati...
...ing, a Chinese by origin and a hunter by professio...facial transplant.// As of now the doctors say tha...peration could be revealed after sixty days. It is...ors reported to the press that Mr. Li has crossed ...
...s a viral infection and spreads by air borne trans...ber of mumps cases. // Statistics show that more t...ses), Nebraska (139), Kansas (205), Illinois (110)...a (unknown) and Okalahoma (unknown). About sixty-s...
...hampion and grandmaster Vishwanathan Anand will no...e Indian chapter of the Bill and Melinda Gates Fou... the awareness about the HIV/AIDS epidemic in Ind...aigns. He is already well known and respected amon...
Other Medicine News:Health News:Mumps Fever Spreads Unabated In US 2Health News:Chess Champion Anand to Champion HIV/AIDS for Avahan 2
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: